Bret Jensen
Bret Jensen is the lead equities analyst with Investors Alley. He's the editor of their newsletters including The Growth Stock Advisor and Biotech Gems.
Bret Jensen's Latest Posts
4 Triple-Digit Winners In Biotech
With important catalysts coming up in 2017, these stocks could soon become triple-digit winners in your portfolio. Start building a well-diversified biotech portfolio with these four stocks. The overall biotech sector continues to be locked in a tight trading range, especially for such a high beta sector of the market. First quarter earnings reports for […]
3 Small Cap Stocks For Apple-Like Returns
Imitating the amazing returns that Apple handed investors since it launched the iPhone is no easy task, but Bret Jensen thinks that these three stocks might be able to come close. Don’t look now, but first quarter earnings seasons is coming up directly ahead. The first quarter for the market was largely a positive one […]
3 Undervalued Stocks On The Verge Of A Breakout
Buying shares at these prices might look like a gift in six month’s time. With multiple catalysts to fuel share price growth on the horizon and a lot of good news not yet baked into the share price, now is a great time to get in. The fairy tale story for biotech investors is buying […]
3 Small Biotech Moonshots To Add To Your Portfolio
As the biotech sector heats up more in 2017, small stocks like the three in this article have already turned in some stellar performances. With the entire sector gaining steam, there’s still plenty of upside left. Bret Jensen recommends adding these three stocks to the portfolio. Sentiment on the biotech sector early in 2017 sure has […]
3 Biotech Stock Beneficiaries Of A Streamlined FDA
With lower approval wait times and decreased regulations on the horizon, long-term investing opportunities in the biotech sector haven’t looked this great in over two years. Take a look at these three stocks in particular as they will reap the most reward from a streamlined FDA. After an approximate gain of 10% in February, the […]
3 Attractive Growth Stocks With Near-Term Catalysts
The market is off to a much stronger start this year than the bloodbath equities were greeted with to begin 2016. Biotech, after a dismal 18 months of underperformance is no exception. Sentiment on this beaten down part of the market started to improve immediately after the unexpected election result in November. The specter of […]
3 Turnaround Stocks For Quick Gains In 2017
After watching the biggest turnaround story in sports on Sunday night, Bret Jensen was inspired to pick out three stocks that have been “left for dead” by the market but have great chances to be resurrected in 2017. Each of these stocks has a tough road ahead but if successful could return investors huge wads […]
The 3 Golden Rules Of Successful Biotech Investing
If you want to invest successfully in one of the few sectors where 1,000% gains are anything but unusual, follow these three “golden rules” that Bret Jensen has developed over his decades-long career. The 45th President of the United States will be inaugurated this week and the stock market has started out 2017 on much […]
3 Stocks Under $10 With Breakout Potential
After executing perfectly on their business plans in 2016, these three stocks look set to reap the profits in 2017. With buyout potential and higher share prices expected in the New Year, adding these three stocks to your portfolio today looks like a smart move. It is hard to believe 2016 has already come and […]
3 Fast-Growth Stocks With Home Run Potential
With massive growth potential over the next few years and solid floors beneath their share prices, consider these three stocks shared today. All three have recently seen their business prospects brighten and now is a great time to buy. Bret Jensen shares why. The end of 2016 is around the corner, and it has been […]
3 Biotech Stocks Set To Soar Under Republican Leadership
After being the market’s whipping boy for the last year, the biotech sector looks ready to rebound under a pro-business White House. Already, many stocks have shot up over 50%, but Bret Jensen shares three today that still have plenty of upside backed up by strong products already on the market. The biotech sector has […]
